Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. Its poor response to current treatment options in advanced stages and the need for efficient diagnosis in early stages call for the development of new therapeutic and diagnostic strategies. Some of them are based on the use of nanometric materials as carriers and releasers of therapeutic agents and fluorescent molecules, or even on the utilization of magnetic materials that provide very interesting properties. These nanoformulations present several advantages compared with the free molecular cargo, including increased drug solubility, bioavailability, stability, and tumor specificity. Moreover, tumor multidrug resistance has been decreased in some cases, leading to improved treatment effectiveness by reducing drug dose and potential side effects. Here, we present an updated overview of the latest advances in clinical research, in vivo studies, and patents regarding the application of nanoformulations in the treatment of CRC. Based on the information gathered, a wide variety of nanomaterials are being investigated in clinical research, even in advanced phases, i.e., close to reaching the market. In sum, these novel materials can offer remarkable advantages with respect to current therapies, which could be complemented or even replaced by these nanosystems in the near future.
Similar content being viewed by others
Abbreviations
- 5-FU:
-
5-Fluorouracil
- FOLFIRI:
-
5-FU/LV/IRI
- FOLFIRINOX:
-
5-FU/LV/IRI/OXA
- FOLFOX:
-
5-FU/LV/OXA
- HCPT:
-
10-Hydroxycamptothecin
- Apt:
-
Aptamer
- AD:
-
Arginine deiminase
- BC:
-
Breast cancer
- BCRP:
-
Breast cancer resistance protein
- CAP:
-
Capecitabine
- CRT:
-
Chemoradiotherapy
- CRC:
-
Colorectal cancer
- TPGS:
-
d-α-Tocopherol polyethylene glycol 1000 succinate
- DPD:
-
Dihydropyrimidine dehydrogenase
- DOX:
-
Doxorubicin
- EGFR:
-
Epidermal growth factor receptor
- EpCAM:
-
Epithelial cell adhesion molecule
- FUPEP:
-
FOLFIRI and PEP02
- GR:
-
Glutathione reductase
- HNM:
-
Head and neck melanoma
- HT:
-
Hyperthermia
- IRI:
-
Irinotecan
- LV or FOL:
-
Leucovorin or folinic acid
- LC:
-
Lung cancer
- MDR:
-
Multidrug resistance
- NPs:
-
Nanoparticles
- OXA:
-
Oxaliplatin
- PGP:
-
P-glycoprotein
- PEDF:
-
Pigment epithelium-derived factor
- PEG:
-
Poly (ethylene glycol)
- PEI:
-
Polyetherimide
- C225-PCQD:
-
Porphyrin carbon quantum dots conjugated with cetuximab
- PTT:
-
Photothermal therapy
- anti-PDL1:
-
Programmed cell death-1 ligand-1 antibody
- PCFT:
-
Proton-coupled folate transporter
- RT:
-
Radiotherapy
- RFC-1:
-
Reduced folate transporter 1
- shRNA:
-
Short hairpin RNA molecule
- SECs:
-
Sinusoidal endothelial cells
- SPIONs:
-
Superparamagnetic iron oxide nanoparticles
- TS:
-
Thymidylate synthase
- Tfr:
-
Transferrin
- TPP:
-
Triphenylphosphonium
- TDP1:
-
Tyrosyl-DNA phosphodiesterase 1
- UGT:
-
UDP-glucuronosyltransferases
- VEGFR:
-
Vascular endothelial growth factor receptor
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.
The Lancet null. GLOBOCAN 2018: counting the toll of cancer. Lancet Lond Engl. 2018;392:985. https://doi.org/10.1016/S0140-6736(18)32252-9.
Kotelevets L, Chastre E, Desmaële D, Couvreur P. Nanotechnologies for the treatment of colon cancer: from old drugs to new hope. Int J Pharm. 2016;514:24–40. https://doi.org/10.1016/j.ijpharm.2016.06.005.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primer. 2015;1:15065. https://doi.org/10.1038/nrdp.2015.65.
Bevan R, Rutter MD. Colorectal cancer screening-who, how, and when? Clin Endosc. 2018;51:37–49. https://doi.org/10.5946/ce.2017.141.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80. https://doi.org/10.1016/S0140-6736(19)32319-0.
Yiu AJ, Yiu CY. Biomarkers in colorectal cancer. Anticancer Res. 2016;36:1093–102.
Tauriello DVF, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97–119. https://doi.org/10.1002/1878-0261.12018.
Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, et al. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res. 2003;9:1338–46.
Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016;7:106–13. https://doi.org/10.5306/wjco.v7.i1.106.
Fernández Montes A, Martínez Lago N, Covela Rúa M, de la Cámara GJ, González Villaroel P, Méndez Méndez JC, et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: prognostic and predictive markers. Cancer Med. 2019;8:882–9. https://doi.org/10.1002/cam4.1903.
Seeber A, Gastl G. Targeted therapy of colorectal cancer. Oncol Res Treat. 2016;39:796–802.
Peeters M, Cervantes A, Moreno Vera S, Taieb J. Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. Future Oncol Lond Engl. 2018;14:1629–45. https://doi.org/10.2217/fon-2018-0147.
Wu SY, Huang YJ, Tzeng YM, Huang CYF, Hsiao M, Wu ATH, et al. Destruxin B suppresses drug-resistant colon tumorigenesis and stemness is associated with the upregulation of mir-214 and downregulation of mTOR/β-catenin pathway. Cancers. 2018;10. https://doi.org/10.3390/cancers10100353.
Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Mol Basel Switz. 2008;13:1551–69.
DeNardo GL, DeNardo SJ. Concepts, consequences, and implications of theranosis. Semin Nucl Med. 2012;42:147–50. https://doi.org/10.1053/j.semnuclmed.2011.12.003.
Alibolandi M, Hoseini F, Mohammadi M, Ramezani P, Einafshar E, Taghdisi SM, et al. Curcumin-entrapped MUC-1 aptamer targeted dendrimer-gold hybrid nanostructure as a theranostic system for colon adenocarcinoma. Int J Pharm. 2018;549:67–75. https://doi.org/10.1016/j.ijpharm.2018.07.052.
Odin E, Sondén A, Gustavsson B, Carlsson G, Wettergren Y. Expression of folate pathway genes in stage III colorectal cancer correlates with recurrence status following adjuvant bolus 5-FU-based chemotherapy. Mol Med Camb Mass. 2015;21:597–604. https://doi.org/10.2119/molmed.2014.00192.
Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, et al. Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance. Mol Oncol. 2015;9:1169–85. https://doi.org/10.1016/j.molonc.2015.02.008.
Dienstmann R, Salazar R, Tabernero J. Overcoming resistance to anti-EGFR therapy in colorectal cancer. Am Soc Clin Oncol Educ Book. 2015;e149–156. https://doi.org/10.14694/EdBook_AM.2015.35.e149.
Morris SA, Farrell D, Grodzinski P. Nanotechnologies in cancer treatment and diagnosis. J Natl Compr Cancer Netw JNCCN. 2014;12:1727–33.
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20–37. https://doi.org/10.1038/nrc.2016.108.
Swain S, Sahu PK, Beg S, Babu SM. Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv. 2016;13:1290–302.
Lai P, Daear W, Löbenberg R, Prenner EJ. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d,l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces. 2014;118:154–63. https://doi.org/10.1016/j.colsurfb.2014.03.017.
Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116:2602–63. https://doi.org/10.1021/acs.chemrev.5b00346.
Maeda H. Polymer therapeutics and the EPR effect. J Drug Target. 2017;25:781–5. https://doi.org/10.1080/1061186X.2017.1365878.
Banerjee A, Pathak S, Subramanium VD, G D, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today. 2017;22:1224–32. https://doi.org/10.1016/j.drudis.2017.05.006.
Yue X, Dai Z. Liposomal nanotechnology for cancer theranostics. Curr Med Chem. 2018;25:1397–408. https://doi.org/10.2174/0929867324666170306105350.
Zeng WJ, Peng CW, Yuan JP, Cui R, Li Y. Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification. Int J Nanomedicine. 2015;10:1759–68. https://doi.org/10.2147/IJN.S70228.
Babu LT, Paira P. Current application of quantum dots (QD) in cancer therapy: a review. Mini Rev Med Chem. 2017;17:1406–15. https://doi.org/10.2174/1389557517666170315125504.
Viswanath B, Kim S, Lee K. Recent insights into nanotechnology development for detection and treatment of colorectal cancer. Int J Nanomedicine. 2016;11:2491–504. https://doi.org/10.2147/IJN.S108715.
Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12:4669–84.
Kesharwani SS, Kaur S, Tummala H, Sangamwar AT. Overcoming multiple drug resistance in cancer using polymeric micelles. Expert Opin Drug Deliv. 2018;15:1127–42. https://doi.org/10.1080/17425247.2018.1537261.
Mignani S, Rodrigues J, Tomas H, Zablocka M, Shi X, Caminade AM, et al. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev. 2018;47:514–32. https://doi.org/10.1039/c7cs00550d.
Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. 2015;10:975–99. https://doi.org/10.2147/IJN.S68861.
Euliss LE, DuPont JA, Gratton S, DeSimone J. Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev. 2006;35:1095–104.
Naeem M, Awan UA, Subhan F, Cao J, Hlaing SP, Lee J, et al. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Arch Pharm Res. 2020;43:153–69. https://doi.org/10.1007/s12272-020-01219-0.
Nakamura H, Fang J, Jun F, Maeda H. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv. 2015;12:53–64. https://doi.org/10.1517/17425247.2014.955011.
Casadó A, Sagristá ML, Mora M. Formulation and in vitro characterization of thermosensitive liposomes for the delivery of irinotecan. J Pharm Sci. 2014;103:3127–38. https://doi.org/10.1002/jps.24097.
Feng ST, Li J, Luo Y, Yin T, Cai H, Wang Y, et al. pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells. PLoS One. 2014;9:e100732. https://doi.org/10.1371/journal.pone.0100732.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102. https://doi.org/10.1186/1556-276X-8-102.
Pan ZZ, Wang HY, Zhang M, Lin TT, Zhang WY, Zhao PF, et al. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacol Sin. 2016;37:1110–20. https://doi.org/10.1038/aps.2016.48.
Jiang Y, Guo Z, Fang J, Wang B, Lin Z, Chen ZS, et al. A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer. Mater Sci Eng C Mater Biol Appl. 2020;107:110224. https://doi.org/10.1016/j.msec.2019.110224.
Wang B, Wu S, Lin Z, Jiang Y, Chen Y, Chen ZS, et al. A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor. Int J Nanomedicine. 2018;13:8411–27. https://doi.org/10.2147/IJN.S184728.
Negi LM, Jaggi M, Joshi V, Ronodip K, Talegaonkar S. Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer. Int J Biol Macromol. 2015;73:222–35. https://doi.org/10.1016/j.ijbiomac.2014.11.026.
Juang V, Chang CH, Wang CS, Wang HE, Lo YL. pH-responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy. Small Weinh Bergstr Ger. 2019;15(e1903296). https://doi.org/10.1002/smll.201903296.
Shao M, Chang C, Liu Z, Chen K, Zhou Y, Zheng G, et al. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance. Colloids Surf B Biointerfaces. 2019;183:110427. https://doi.org/10.1016/j.colsurfb.2019.110427.
Zhang X, Zhao M, Cao N, Qin W, Zhao M, Wu J, et al. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater Sci. 2020;8:1885–96. https://doi.org/10.1039/c9bm01927h.
Wei Y, Gu X, Sun Y, Meng F, Storm G, Zhong Z. Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. J Control Release Off J Control Release Soc. 2020;319:407–15. https://doi.org/10.1016/j.jconrel.2020.01.012.
Shi H, Liang GF, Li Y, Li JH, Jing AH, Feng WP, et al. Preparation and evaluation of upconversion nanoparticles based miRNA delivery carrier in colon cancer mice model. J Biomed Nanotechnol. 2019;15:2240–50. https://doi.org/10.1166/jbn.2019.2840.
Zhong Y, Su T, Shi Q, Feng Y, Tao Z, Huang Q, et al. Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment. Int J Nanomedicine. 2019;14:8543–60. https://doi.org/10.2147/IJN.S219820.
Le Goas M, Paquet M, Paquirissamy A, Guglielmi J, Compin C, Thariat J, et al. Improving 131I radioiodine therapy by hybrid polymer-grafted gold nanoparticles. Int J Nanomedicine. 2019;14:7933–46. https://doi.org/10.2147/IJN.S211496.
Zhao Y, Xu J, Le VM, Gong Q, Li S, Gao F, et al. EpCAM Aptamer-functionalized cationic liposome-based nanoparticles loaded with miR-139-5p for targeted therapy in colorectal cancer. Mol Pharm. 2019;16:4696–710. https://doi.org/10.1021/acs.molpharmaceut.9b00867.
Zhong Y, Ma Z, Wang F, Wang X, Yang Y, Liu Y, et al. In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles. Nat Biotechnol. 2019;37:1322–31. https://doi.org/10.1038/s41587-019-0262-4.
Simón M, Norregaard K, Jørgensen JT, Oddershede LB, Kjaer A. Fractionated photothermal therapy in a murine tumor model: comparison with single dose. Int J Nanomedicine. 2019;14:5369–79. https://doi.org/10.2147/IJN.S205409.
Chen Y, Li N, Xu B, Wu M, Yan X, Zhong L, et al. Polymer-based nanoparticles for chemo/gene-therapy: evaluation its therapeutic efficacy and toxicity against colorectal carcinoma. Biomed Pharmacother Biomedecine Pharmacother. 2019;118:109257. https://doi.org/10.1016/j.biopha.2019.109257.
Tsakiris N, Papavasileiou M, Bozzato E, Lopes A, Vigneron AM, Préat V. Combinational drug-loaded lipid nanocapsules for the treatment of cancer. Int J Pharm. 2019;569:118588. https://doi.org/10.1016/j.ijpharm.2019.118588.
Xing J, Zhang X, Wang Z, Zhang H, Chen P, Zhou G, et al. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy. Int J Nanomedicine. 2019;14:5201–13. https://doi.org/10.2147/IJN.S204965.
Li C, Cai G, Song D, Gao R, Teng P, Zhou L, et al. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer. Biomater Sci. 2019;7:3627–39. https://doi.org/10.1039/c9bm00613c.
Rosch JG, Landry MR, Thomas CR, Sun C. Enhancing chemoradiation of colorectal cancer through targeted delivery of raltitrexed by hyaluronic acid coated nanoparticles. Nanoscale. 2019;11:13947–60. https://doi.org/10.1039/c9nr04320a.
Cheng G, Zhang X, Chen Y, Lee RJ, Wang J, Yao J, et al. Anticancer activity of polymeric nanoparticles containing linoleic acid-SN38 (LA-SN38) conjugate in a murine model of colorectal cancer. Colloids Surf B Biointerfaces. 2019;181:822–9. https://doi.org/10.1016/j.colsurfb.2019.06.020.
Zhang X, Men K, Zhang Y, Zhang R, Yang L, Duan X. Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy. Int J Nanomedicine. 2019;14:2733–51. https://doi.org/10.2147/IJN.S198747.
Xu M, Wen Y, Liu Y, Tan X, Chen X, Zhu X, et al. Hollow mesoporous ruthenium nanoparticles conjugated bispecific antibody for targeted anti-colorectal cancer response of combination therapy. Nanoscale. 2019;11:9661–78. https://doi.org/10.1039/c9nr01904a.
Jain A, Jain R, Jain S, Khatik R, Veer KD. Minicapsules encapsulating nanoparticles for targeting, apoptosis induction and treatment of colon cancer. Artif Cells Nanomedicine Biotechnol. 2019;47:1085–93. https://doi.org/10.1080/21691401.2019.1593848.
Li HQ, Ye W-L, Huan ML, Cheng Y, Liu DZ, Cui H, et al. Mitochondria and nucleus delivery of active form of 10-hydroxycamptothecin with dual shell to precisely treat colorectal cancer. Nanomed. 2019;14:1011–32. https://doi.org/10.2217/nnm-2018-0227.
Gu X, Wei Y, Fan Q, Sun H, Cheng R, Zhong Z, et al. cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo. J Control Release. 2019;301:110–8. https://doi.org/10.1016/j.jconrel.2019.03.005.
Zhao C, Cao W, Zheng H, Xiao Z, Hu J, Yang L, et al. Acid-responsive nanoparticles as a novel oxidative stress-inducing anticancer therapeutic agent for colon cancer. Int J Nanomedicine. 2019;14:1597–618. https://doi.org/10.2147/IJN.S189923.
Abed Z, Beik J, Laurent S, Eslahi N, Khani T, Davani ES, et al. Iron oxide-gold core-shell nano-theranostic for magnetically targeted photothermal therapy under magnetic resonance imaging guidance. J Cancer Res Clin Oncol. 2019;145:1213–9. https://doi.org/10.1007/s00432-019-02870-x.
Qiu R, Qian F, Wang X, Li H, Wang L. Targeted delivery of 20(S)-ginsenoside Rg3-based polypeptide nanoparticles to treat colon cancer. Biomed Microdevices. 2019;21:18. https://doi.org/10.1007/s10544-019-0374-0.
Mulens-Arias V, Nicolás-Boluda A, Gehanno A, Balfourier A, Carn F, Gazeau F. Polyethyleneimine-assisted one-pot synthesis of quasi-fractal plasmonic gold nanocomposites as a photothermal theranostic agent. Nanoscale. 2019;11:3344–59. https://doi.org/10.1039/c8nr09849b.
Ren Y, Li X, Han B, Zhao N, Mu M, Wang C, et al. Improved anti-colorectal carcinomatosis effect of tannic acid co-loaded with oxaliplatin in nanoparticles encapsulated in thermosensitive hydrogel. Eur J Pharm Sci. 2019;128:279–89. https://doi.org/10.1016/j.ejps.2018.12.007.
Xie K, Song S, Zhou L, Wan J, Qiao Y, Wang M, et al. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly. Int J Pharm. 2019;556:159–71. https://doi.org/10.1016/j.ijpharm.2018.12.017.
Sesarman A, Tefas L, Sylvester B, Licarete E, Rauca V, Luput L, et al. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. Drug Deliv Transl Res. 2019;9:260–72. https://doi.org/10.1007/s13346-018-00598-8.
Thébault CJ, Ramniceanu G, Michel A, Beauvineau C, Girard C, Seguin J, et al. In vivo evaluation of magnetic targeting in mice colon tumors with ultra-magnetic liposomes monitored by MRI. Mol Imaging Biol. 2019;21:269–78. https://doi.org/10.1007/s11307-018-1238-3.
Näkki S, Wang JTW, Wu J, Fan L, Rantanen J, Nissinen T, et al. Designed inorganic porous nanovector with controlled release and MRI features for safe administration of doxorubicin. Int J Pharm. 2019;554:327–36. https://doi.org/10.1016/j.ijpharm.2018.10.074.
Afsharzadeh M, Abnous K, Yazdian-Robati R, Ataranzadeh A, Ramezani M, Hashemi M. Formulation and evaluation of anticancer and antiangiogenesis efficiency of PLA-PEG nanoparticles loaded with galbanic acid in C26 colon carcinoma, in vitro and in vivo. J Cell Physiol mayo de. 2019;234:6099–107.
Hao M, Kong C, Jiang C, Hou R, Zhao X, Li J, et al. Polydopamine-coated Au-Ag nanoparticle-guided photothermal colorectal cancer therapy through multiple cell death pathways. Acta Biomater. 2019;83:414–24. https://doi.org/10.1016/j.actbio.2018.10.032.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. https://doi.org/10.1056/NEJMoa1500596.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68. https://doi.org/10.1056/NEJMra1703481.
Luo L, Yang J, Zhu C, Jiang M, Guo X, Li W, et al. Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. J Control Release. 2018;278:87–99. https://doi.org/10.1016/j.jconrel.2018.04.002.
Song W, Shen L, Wang Y, Liu Q, Goodwin TJ, Li J, et al. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. 2018;9:2237. https://doi.org/10.1038/s41467-018-04605-x.
Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, et al. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. 2020;6:eaaw6071. https://doi.org/10.1126/sciadv.aaw6071.
Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489–96. https://doi.org/10.1038/nmat4822.
Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, et al. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2017;12:648–54. https://doi.org/10.1038/nnano.2017.52.
Alabi C, Vegas A, Anderson D. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol. 2012;12:427–33. https://doi.org/10.1016/j.coph.2012.05.004.
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–66. https://doi.org/10.1038/nrc2602.
Tian X, Nguyen M, Foote HP, Caster JM, Roche KC, Peters CG, et al. CRLX101, a nanoparticle-drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and HIF1α. Cancer Res. 2017;77:112–22. https://doi.org/10.1158/0008-5472.CAN-15-2951.
Chibaudel B, Maindrault-Gœbel F, Bachet J-B, Louvet C, Khalil A, Dupuis O, et al. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med. 2016;5:676–83. https://doi.org/10.1002/cam4.635.
Lyon PC, Griffiths LF, Lee J, Chung D, Carlisle R, Wu F, et al. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound. 2017;5:28. https://doi.org/10.1186/s40349-017-0104-0.
Golan T, Grenader T, Ohana P, Amitay Y, Shmeeda H, La-Beck NM, et al. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. Cancer Med. 2015;4:1472–83. https://doi.org/10.1002/cam4.491.
Maitra R, Halpin PA, Karlson KH, Page RL, Paik DY, Leavitt MO, et al. Differential effects of mitomycin C and doxorubicin on P-glycoprotein expression. Biochem J. 2001;355:617–24.
Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, et al. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014;61:1792–7. https://doi.org/10.1002/pbc.25105.
Garrett CR, Bekaii-Saab TS, Ryan T, Fisher GA, Clive S, Kavan P, et al. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 2013;119(24):4223–30. https://doi.org/10.1002/cncr.28358.
Abdellatif AAH, Zayed G, El-Bakry A, Zaky A, Saleem IY, Tawfeek HM. Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors. Drug Dev Ind Pharm. 2016;42:1782–91. https://doi.org/10.3109/03639045.2016.1173052.
Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, et al. Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors. Clin Cancer Res. 2015;21:2480–6. https://doi.org/10.1158/1078-0432.CCR-14-2610.
Miyazaki K, Takaku H, Umeda M, Fujita T, Huang WD, Kimura T, et al. Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line. Cancer Res. 1990;50:4522–7.
Ishida T, Huang CL, Wada H; Delta-Fly Pharma, Inc., Tokushima-shi (JP). Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof. United States US2012301537A1. 2012.
Fitzgerald JB, Kearns JD, Lee H, Nering RC; Merrimack Pharmaceuticals Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and liposomal irinotecan. World Intellectual Property Organization WO2017172678A1. 2017.
Zhu X, Wong Wk, Wu F; Hong Kong Baptist University, Hong Kong (HK). Conjugated porphyrin carbon quantum dots for targeted photodynamic therapy. United States US20180125976. 2018.
Dash AK, Trickler WJ; Creighton University, Omaha, NE (US). Mucoadhesive nanoparticles for cancer treatment. United States Patent US8242165B2. 2012.
Shieh DB, Yeh CS, Chen DH, Wu YN, Wu PC; National Cheng Kung University, Tainan (TW). Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex, and method for treating cancer by using the pharmaceutical composition. United States Patent US8673358B2. 2014.
Funding
This work was funded by the Consejería de Salud de la Junta de Andalucía (PI-0102-2017) and by the Group CTS-107. This work was also partially supported by a grant from the Instituto de Salud Carlos III (ISCIII) (PI19/01478) (FEDER).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Cabeza, L., Perazzoli, G., Mesas, C. et al. Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents. AAPS PharmSciTech 21, 178 (2020). https://doi.org/10.1208/s12249-020-01731-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12249-020-01731-y